
NRSN
Neurosense Therapeutics Ltd
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
2.030
Open
2.030
VWAP
2.00
Vol
225.85K
Mkt Cap
48.70M
Low
1.935
Amount
452.04K
EV/EBITDA(TTM)
--
Total Shares
18.04M
EV
45.32M
EV/OCF(TTM)
--
P/S(TTM)
--
NeuroSense Therapeutics Ltd is an Israel-based clinical-stage pharmaceutical company. The Company is active in field of drug development and treatment offers Amyotrophic Lateral Sclerosis (ALS) patients, as well as other neurodegenerative diseases. The Company's lead product candidate, PrimeC, is an oral formulation of a fixed dose combination composed of a specific ratio of drugs. In addition to PrimeC, the Company has initiated research and development efforts in Alzheimer's disease and Parkinson's disease
Show More
2 Analyst Rating

589.66% Upside
Wall Street analysts forecast NRSN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NRSN is 14.00 USD with a low forecast of 14.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
1 Hold
0 Sell
Moderate Buy

589.66% Upside
Current: 2.030

Low
14.00
Averages
14.00
High
14.00

589.66% Upside
Current: 2.030

Low
14.00
Averages
14.00
High
14.00
D. Boral Capital
Jason Kolbert
Buy
initiated
$14
2025-05-12
Reason
D. Boral Capital
Jason Kolbert
Price Target
$14
2025-05-12
initiated
Buy
Reason
Maxim Group
Naz Rahman
Strong Buy
to
Hold
Downgrades
n/a
2024-12-16
Reason
Maxim Group
Naz Rahman
Price Target
n/a
2024-12-16
Downgrades
Strong Buy
to
Hold
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Neurosense Therapeutics Ltd (NRSN.O) is -4.46, compared to its 5-year average forward P/E of -1.89. For a more detailed relative valuation and DCF analysis to assess Neurosense Therapeutics Ltd 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-1.89
Current PE
-4.46
Overvalued PE
-1.09
Undervalued PE
-2.68
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financials
Annual
Quarterly
FY2024Q4
YoY :
-100.00%
N/A
Operating Profit
FY2024Q4
YoY :
-100.00%
N/A
Net Income after Tax
FY2024Q4
YoY :
-100.00%
N/A
EPS - Diluted
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
NRSN News & Events
Events Timeline
2025-01-06 (ET)
2025-01-06
08:06:45
NeuroSense regains Nasdaq compliance

2024-12-23 (ET)
2024-12-23
08:02:25
NeuroSense enters binding term sheet to advance PrimeC for ALS

2024-12-06 (ET)
2024-12-06
15:34:27
NeuroSense files to sell 6.6M ordinary shares for holders

Sign Up For More Events
Sign Up For More Events
News
9.0
05-12BenzingaWhy This Nano-Cap Stock Might Skyrocket To $14, Per Analyst Insights
4.0
05-12BenzingaThis NeuroSense Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Monday
5.0
05-07PRnewswireNeuroSense Therapeutics Announces Successful Completion of Commercial Manufacturing Scale-Up for PrimeC in Preparation for Potential Canadian Market Launch
Sign Up For More News
People Also Watch

ENLV
Enlivex Therapeutics Ltd
1.122
USD
-1.75%

UTSI
UTStarcom Holdings Corp
2.510
USD
+1.21%

PLUR
Pluri Inc
5.156
USD
+0.90%

LVTX
LAVA Therapeutics NV
1.430
USD
-2.05%

HUDI
Huadi International Group Co., Ltd.
1.250
USD
-2.72%

KFFB
Kentucky First Federal Bancorp
3.251
USD
+0.03%

LRE
Lead Real Estate Co Ltd
1.840
USD
-6.12%

TRT
Trio-Tech International
5.390
USD
-6.91%

MXC
Mexco Energy Corp
8.030
USD
-1.11%

EZFL
EzFill Holdings Inc
0
USD
-3.14%
FAQ

What is Neurosense Therapeutics Ltd (NRSN) stock price today?
The current price of NRSN is 2.03 USD — it has increased 0 % in the last trading day.

What is Neurosense Therapeutics Ltd (NRSN)'s business?

What is the price predicton of NRSN Stock?

What is Neurosense Therapeutics Ltd (NRSN)'s revenue for the last quarter?

What is Neurosense Therapeutics Ltd (NRSN)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Neurosense Therapeutics Ltd (NRSN)'s fundamentals?

How many employees does Neurosense Therapeutics Ltd (NRSN). have?
